Scarica l'app Stockscreener
10.07
0.10%
-0.0104
Dopo l'orario di chiusura:
10.08
0.010
+0.10%
Precedente Chiudi:
$10.08
Aprire:
$10.08
Volume 24 ore:
9,961
Relative Volume:
0.16
Capitalizzazione di mercato:
$220.61M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-0.10%
1M Prestazione:
+0.30%
6M Prestazione:
+20.48%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$10.07
$10.09
Intervallo di 1 settimana:
$10.07
$10.10
Portata 52W:
$10.00
$10.20
Translational Development Acquisition Corp Stock (TDAC) Company Profile
Nome
Translational Development Acquisition Corp
Settore
Industria
Telefono
(413) 204-2769
Indirizzo
52 E 83RD ST., NEW YORK
Confronta TDAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TDAC
Translational Development Acquisition Corp
|
10.07 | 220.61M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
7.11 | 2.05B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.14 | 696.25M | 0 | 16.92M | -1.35M | 0.29 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.66 | 459.71M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.27 | 451.61M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.09 | 449.74M | 0 | 0 | 0 | 0.00 |
Translational Development Acquisition Corp Stock (TDAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-21 | Iniziato | Northland Capital | Outperform |
Translational Development Acquisition Corp Borsa (TDAC) Ultime notizie
Artis BioSolutions Emerges from Stealth, Announces Acquisition of Landmark Bio - BioSpace
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - Yahoo Finance
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Major SPAC Update: TDACU Splits Units into Separate Shares & Warrants Trading - Stock Titan
Trident Acquisitions stock hits 52-week high of $10.08 By Investing.com - Investing.com Australia
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
Ocean Biomedical Announces Breakthrough Findings in - GlobeNewswire
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com UK
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - Stock Titan
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - Stock Titan
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
Rapid effects of valproic acid on the fetal brain transcriptome: implications for brain development and autism - Nature
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel - GlobeNewswire
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Ipsen and Foreseen Biotechnology announce exclusive global - GlobeNewswire
Research and development center Cambridge, Massachusetts - Bristol Myers Squibb (BMS)
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering and Biotechnology News
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering and Biotechnology News
Pioneering Innovative Drug Development at Cambridge Crossing Facility - Bristol Myers Squibb (BMS)
SSI Strategy and NDA Group Combine to Form Best-in-Class Global Life Sciences Consultancy - Business Wire
FirstEnergy issues earnings report - 69News WFMZ-TV
Spatial Genomics and Transcriptomics Market Size Report, 2032 - Global Market Insights
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure - News-Medical.Net
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
IPO Pricings Archives - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Why Kymab Agreed to be Acquired by Sanofi - Timmerman Report
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
VeriSIM Life Announces Acquisition of Molomics Biotech - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
BioSpace Movers & Shakers, Jan. 21 - BioSpace
Third Rock Ventures Promotes David Kaufman, M.D., Ph.D., to Partner - citybiz
Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing - BioSpace
Research and Development grant cheat sheet - The University of Sydney
Crown Bioscience Unveils New Identity - Business Wire
A red blood cell disease meets a company with a plasma protein heritage - Nature
CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings - Business Wire
BioSpace Movers & Shakers, March 19 - BioSpace
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. - Business Wire
Translational Development Acquisition Corp Azioni (TDAC) Dati Finanziari
Non sono disponibili dati finanziari per Translational Development Acquisition Corp (TDAC). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.31%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):